ADBE vs LLY: Which Is the Better Buy?
Side-by-side comparison of Adobe Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-16.
Adobe Inc. · Technology
$248.16
+163.1% upside to fair value
High Conviction
Grade B
VS
Eli Lilly and Company · Healthcare
$939.47
+71.1% upside to fair value
High Conviction
Grade A
QuantHub Verdict
ADBE has more upside to fair value
(+163.1%).
ADBE trades at a lower forward P/E
(14.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ADBE |
LLY |
| Current Price |
$248.16 |
$939.47 |
| Fair Value Estimate |
$653.00 |
$1,607.00 |
| Upside to Fair Value |
+163.1%
|
+71.1%
|
| Market Cap |
$101.2B |
$887.6B |
| Forward P/E |
14.1x
|
27.4x
|
| EV / EBITDA |
—
|
35.8x
|
| Price / Sales |
4.1x
|
14.8x
|
| Price / FCF |
9.8x
|
107.6x
|
| Revenue Growth YoY |
+3.3%
|
+44.7%
|
| Gross Margin |
89.1%
|
83.8%
|
| Operating Margin |
36.6%
|
45.6%
|
| Return on Equity |
62.3%
|
77.8%
|
| Dividend Yield |
— |
0.56% |
| FCF Yield |
10.2%
|
0.93%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Adobe Inc. develops industry-leading creative software, digital experience platforms, and publishing tools, powering digital content creation and marketing for professionals worldwide. The business excels with high gross margins above 89%, a sticky subscription model driving recurring revenue over $17B ARR, and dominant moats in digital media, though it faces intensifying AI competition and slowi…
Eli Lilly remains the dominant GLP-1 franchise holder with Mounjaro and Zepbound generating $36.5B combined in 2025 on 45% total revenue growth to $65.2B. The company guided $80-83B for 2026, well above prior Street consensus, and launched Foundayo (oral GLP-1, FDA approved April 2026) with $1.5B pre-built inventory. At $939 the stock trades at 14.8x P/S, right at its 5-year median, and 27.4x for…
Accumulation Zones
| Metric |
ADBE |
LLY |
| Zone Low |
$490.00 |
$1,205.00 |
| Zone High |
$555.00 |
$1,366.00 |
| In Buy Zone? |
Yes
|
Yes
|